Nicox’s Licensee Bausch + Lomb Secures Approval of Vyzulta in Colombia

Nicox announced that its partner, Bausch + Lomb, has received approval for latanoprostene bunod ophthalmic solution, 0.024% (marketed as Vyzulta In the United States) in Colombia, where it will be marketed under the brand name Cliropta.

Vyzulta is currently commercialized in the United States, Canada and Argentina and approved in 5 other territories–Colombia, Hong Kong, Mexico, Taiwan and Ukraine-for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension.  

Bausch + Lomb will continue seeking approvals in territories where the clinical data package, part of the U.S. New Drug Application (NDA), can be used for approval by the regulatory authorities.

Under the terms of the exclusive license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of Vyzulta plus up to $150 million in potential future milestones payments.